- Home
- AEMD vs APM Comparison
AEMD vs APM Comparison
Compare AEMD & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- APM
- Stock Information
- Founded
- AEMD 1984
- APM 2010
- Country
- AEMD United States
- APM United Kingdom
- Employees
- AEMD N/A
- APM N/A
- Industry
- AEMD Medical/Dental Instruments
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- APM Health Care
- Exchange
- AEMD Nasdaq
- APM Nasdaq
- Market Cap
- AEMD 8.2M
- APM 6.7M
- IPO Year
- AEMD N/A
- APM 2018
- Fundamental
- Price
- AEMD $0.42
- APM $0.92
- Analyst Decision
- AEMD Strong Buy
- APM
- Analyst Count
- AEMD 1
- APM 0
- Target Price
- AEMD $7.00
- APM N/A
- AVG Volume (30 Days)
- AEMD 260.5K
- APM 51.3K
- Earning Date
- AEMD 02-12-2025
- APM 04-29-2025
- Dividend Yield
- AEMD N/A
- APM N/A
- EPS Growth
- AEMD N/A
- APM N/A
- EPS
- AEMD N/A
- APM 0.00
- Revenue
- AEMD N/A
- APM N/A
- Revenue This Year
- AEMD N/A
- APM $157,729.10
- Revenue Next Year
- AEMD N/A
- APM N/A
- P/E Ratio
- AEMD N/A
- APM $262.46
- Revenue Growth
- AEMD N/A
- APM N/A
- 52 Week Low
- AEMD $0.24
- APM $0.46
- 52 Week High
- AEMD $1.85
- APM $11.95
- Technical
- Relative Strength Index (RSI)
- AEMD 34.08
- APM 42.55
- Support Level
- AEMD $0.40
- APM $0.82
- Resistance Level
- AEMD $0.60
- APM $1.08
- Average True Range (ATR)
- AEMD 0.05
- APM 0.09
- MACD
- AEMD -0.01
- APM -0.00
- Stochastic Oscillator
- AEMD 13.41
- APM 39.27
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.